Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine - PubMed (original) (raw)
. 2013 Feb;280(4):1150-66.
doi: 10.1111/febs.12108. Epub 2013 Feb 1.
Affiliations
- PMID: 23286234
- DOI: 10.1111/febs.12108
Free article
Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine
Gareth A Prosser et al. FEBS J. 2013 Feb.
Free article
Abstract
D-cycloserine (DCS) is an antibiotic that is currently used in second-line treatment of tuberculosis. DCS is a structural analogue of D-alanine, and targets two enzymes involved in the cytosolic stages of peptidoglycan synthesis: alanine racemase (Alr) and D-alanine:D-alanine ligase (Ddl). The mechanisms of inhibition of DCS have been well-assessed using Alr and Ddl enzymes from various bacterial species, but little is known regarding the interactions of DCS with the mycobacterial orthologues of these enzymes. We have over-expressed and purified recombinant Mycobacterium tuberculosis Ddl (MtDdl; Rv2981c), and report a kinetic examination of the enzyme with both its native substrate and DCS. MtDdl is activated by K(+), follows an ordered ter ter mechanism and displays distinct affinities for D-Ala at each D-Ala binding site (K(m,D-Ala1) = 0.075 mm, K(m,D-Ala2) = 3.6 mm). ATP is the first substrate to bind and is necessary for subsequent binding of D-alanine or DCS. The pH dependence of MtDdl kinetic parameters indicate that general base chemistry is involved in the catalytic step. DCS was found to competitively inhibit D-Ala binding at both MtDdl D-Ala sites with equal affinity (K(i,DCS1) = 14 μm, K(i,DCS2) = 25 μm); however, each enzyme active site can only accommodate a single DCS molecule at a given time. The pH dependence of K(i,DCS2) revealed a loss of DCS binding affinity at high pH (pK(a) = 7.5), suggesting that DCS binds optimally in the zwitterionic form. The results of this study may assist in the design and development of novel Ddl-specific inhibitors for use as anti-mycobacterial agents.
© 2013 The Authors Journal compilation © 2013 FEBS.
Similar articles
- Structure of the Mycobacterium tuberculosis D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine.
Bruning JB, Murillo AC, Chacon O, Barletta RG, Sacchettini JC. Bruning JB, et al. Antimicrob Agents Chemother. 2011 Jan;55(1):291-301. doi: 10.1128/AAC.00558-10. Epub 2010 Oct 18. Antimicrob Agents Chemother. 2011. PMID: 20956591 Free PMC article. - D-Cycloserine destruction by alanine racemase and the limit of irreversible inhibition.
de Chiara C, Homšak M, Prosser GA, Douglas HL, Garza-Garcia A, Kelly G, Purkiss AG, Tate EW, de Carvalho LPS. de Chiara C, et al. Nat Chem Biol. 2020 Jun;16(6):686-694. doi: 10.1038/s41589-020-0498-9. Epub 2020 Mar 16. Nat Chem Biol. 2020. PMID: 32203411 Free PMC article. - Roles of Mycobacterium smegmatis D-alanine:D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine.
Feng Z, Barletta RG. Feng Z, et al. Antimicrob Agents Chemother. 2003 Jan;47(1):283-91. doi: 10.1128/AAC.47.1.283-291.2003. Antimicrob Agents Chemother. 2003. PMID: 12499203 Free PMC article. - Molecular basis underlying Mycobacterium tuberculosis D-cycloserine resistance. Is there a role for ubiquinone and menaquinone metabolic pathways?
Hong W, Chen L, Xie J. Hong W, et al. Expert Opin Ther Targets. 2014 Jun;18(6):691-701. doi: 10.1517/14728222.2014.902937. Epub 2014 Apr 29. Expert Opin Ther Targets. 2014. PMID: 24773568 Review. - Discovery of novel antibacterial agents: Recent developments in D-alanyl-D-alanine ligase inhibitors.
Qin Y, Xu L, Teng Y, Wang Y, Ma P. Qin Y, et al. Chem Biol Drug Des. 2021 Sep;98(3):305-322. doi: 10.1111/cbdd.13899. Epub 2021 Jun 27. Chem Biol Drug Des. 2021. PMID: 34047462 Review.
Cited by
- Burkholderia pseudomallei d-alanine-d-alanine ligase; detailed characterisation and assessment of a potential antibiotic drug target.
Díaz-Sáez L, Torrie LS, McElroy SP, Gray D, Hunter WN. Díaz-Sáez L, et al. FEBS J. 2019 Nov;286(22):4509-4524. doi: 10.1111/febs.14976. Epub 2019 Jul 16. FEBS J. 2019. PMID: 31260169 Free PMC article. - Development of a one-pot assay for screening and identification of Mur pathway inhibitors in Mycobacterium tuberculosis.
Eniyan K, Kumar A, Rayasam GV, Perdih A, Bajpai U. Eniyan K, et al. Sci Rep. 2016 Oct 13;6:35134. doi: 10.1038/srep35134. Sci Rep. 2016. PMID: 27734910 Free PMC article. - Anti-tuberculosis drug development via targeting the cell envelope of Mycobacterium tuberculosis.
Xu X, Dong B, Peng L, Gao C, He Z, Wang C, Zeng J. Xu X, et al. Front Microbiol. 2022 Dec 21;13:1056608. doi: 10.3389/fmicb.2022.1056608. eCollection 2022. Front Microbiol. 2022. PMID: 36620019 Free PMC article. Review. - Heteroatom-Heteroatom Bond Formation in Natural Product Biosynthesis.
Waldman AJ, Ng TL, Wang P, Balskus EP. Waldman AJ, et al. Chem Rev. 2017 Apr 26;117(8):5784-5863. doi: 10.1021/acs.chemrev.6b00621. Epub 2017 Apr 4. Chem Rev. 2017. PMID: 28375000 Free PMC article. Review. - Emerging Extracellular Molecular Targets for Innovative Pharmacological Approaches to Resistant Mtb Infection.
Italia A, Shaik MM, Peri F. Italia A, et al. Biomolecules. 2023 Jun 16;13(6):999. doi: 10.3390/biom13060999. Biomolecules. 2023. PMID: 37371579 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous